Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Market for MicroRNA Tools and Services Expected to More than Double

By BiotechDaily International staff writers
Posted on 16 Sep 2013
Due to the rapid growth in microRNA (miRNA) research, the markets for reagents and instrumentation in this field as well as for miRNA service providers are expected to more than double over the next several years.

The growth of therapeutic and diagnostic enterprises, higher research funding, and increased outsourcing to contract research organizations should present immense opportunities for the miRNA tools and services market.

Data released in the new Frost & Sullivan (Mountain View, CA, USA) report "Global Analysis of MicroRNA Tools and Services Market" revealed that the market for reagents and instrumentation earned revenues of 110.0 million USD in 2012 and estimated this to more than double to reach 247.7 USD million in 2017.

The miRNA services market, which caters to academic and research institutes, core facilities, and pharmaceutical and biotech companies, earned revenues of 35.1 million USD in 2012, and this is expected to grow to 63.3 million USD in 2017.

Of the various miRNA technologies, which include quantitative real-time polymerase chain reaction (qRT PCR), microarrays, and functional tools, qRT PCR remains the fastest growing, while microarray is gradually being replaced by next-generation sequencing platforms.

"As miRNA research evolves globally and more efficient products are required, the space is burgeoning with technology innovations," said Divyaa Ravishankar, senior research analyst at Frost & Sullivan. "Strategic alliances for product development are taking place, resulting in novel kits for qPCR and new mimics and inhibitors that help researchers shorten their project timeline and get more funding. To sustain product value until then, market participants must continue to offer technology improvements and differentiated features, and strategically compete without making deep pricing cuts that may irreversibly damage market potential. Providing complete workflow solutions and discounts when a customer purchases products along with several different portfolios will simplify purchasing and attract new customers."

Related Links:

Frost & Sullivan



Channels

Genomics/Proteomics

view channel
Image: The bone marrow of mice with normal ether lipid production (top) contains more white blood cells than are found in the bone marrow of mice with ether lipid deficiency (bottom) (Photo courtesy of Washington University School of Medicine).

Inactivating Fatty Acid Synthase Reduces Inflammation by Interfering with Neutrophil Membrane Function

The enzyme fatty acid synthase (FAS) was shown to regulate inflammation by sustaining neutrophil viability through modulation of membrane phospholipid composition. Neutrophils are the most abundant... Read more

Drug Discovery

view channel
Image: Researchers have attached two drugs—TRAIL and Dox—onto graphene strips. TRAIL is most effective when delivered to the external membrane of a cancer cell, while Dox is most effective when delivered to the nucleus, so the researchers designed the system to deliver the drugs sequentially, with each drug hitting a cancer cell where it will do the most damage (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Anticancer Drug Delivery System Utilizes Graphene Strip Transporters

The ongoing search by cancer researchers for targeted drug delivery systems has generated a novel approach that uses graphene strips to transport simultaneously the anticancer agents TRAIL (tumor necrosis... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.